NovoCure Limited (FRA:038)
Germany · Delayed Price · Currency is EUR 10.59
-0.25 (-2.35%)
Last updated: Jan 28, 2026, 8:12 AM CET
NovoCure Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 642.27 | 605.22 | 509.34 | 537.84 | 535.03 | 494.37 | |
Revenue Growth (YoY) | 11.17% | 18.82% | -5.30% | 0.53% | 8.23% | 40.72% |
Cost of Revenue | 157.18 | 136.18 | 127.54 | 114.26 | 114.24 | 106.09 |
Gross Profit | 485.09 | 469.05 | 381.8 | 423.58 | 420.79 | 388.27 |
Selling, General & Admin | 441.97 | 427.21 | 386.97 | 306.41 | 263.18 | 225.45 |
Research & Development | 214.57 | 209.37 | 220.99 | 206.09 | 201.3 | 132.01 |
Operating Expenses | 656.54 | 636.58 | 607.96 | 512.5 | 464.49 | 357.46 |
Operating Income | -171.45 | -167.54 | -226.16 | -88.91 | -43.69 | 30.81 |
Interest Expense | -13.67 | -10.34 | -3.32 | -3.33 | -3.44 | -17.58 |
Interest & Investment Income | 14.07 | 22.72 | 19.64 | 10.96 | 0.79 | 1.79 |
Currency Exchange Gain (Loss) | -0.72 | -0.72 | -0.8 | -3.52 | -4.03 | 2.65 |
Other Non Operating Income (Expenses) | -0.6 | -0.6 | -0.79 | -1.26 | -1.37 | -0.47 |
EBT Excluding Unusual Items | -172.38 | -156.48 | -211.42 | -86.06 | -51.74 | 17.2 |
Merger & Restructuring Charges | -2 | -2 | -6.23 | - | - | - |
Gain (Loss) on Sale of Investments | 28.27 | 28.27 | 26.4 | 4.83 | 0.31 | 1.32 |
Asset Writedown | -0.95 | -0.95 | -0.48 | -0.61 | -0.64 | -0.41 |
Other Unusual Items | -3.44 | - | - | - | - | - |
Pretax Income | -150.5 | -131.16 | -191.74 | -81.85 | -52.08 | 18.1 |
Income Tax Expense | 27.15 | 37.47 | 15.3 | 10.69 | 6.28 | -1.71 |
Net Income | -177.65 | -168.63 | -207.04 | -92.53 | -58.35 | 19.81 |
Net Income to Common | -177.65 | -168.63 | -207.04 | -92.53 | -58.35 | 19.81 |
Shares Outstanding (Basic) | 111 | 108 | 106 | 105 | 103 | 101 |
Shares Outstanding (Diluted) | 111 | 108 | 106 | 105 | 103 | 109 |
Shares Change (YoY) | 2.82% | 1.36% | 1.65% | 1.19% | -5.00% | 11.97% |
EPS (Basic) | -1.61 | -1.56 | -1.95 | -0.88 | -0.56 | 0.20 |
EPS (Diluted) | -1.61 | -1.56 | -1.95 | -0.88 | -0.56 | 0.18 |
Free Cash Flow | -65.17 | -69.22 | -100.43 | 9.43 | 58.59 | 84.18 |
Free Cash Flow Per Share | -0.59 | -0.64 | -0.94 | 0.09 | 0.57 | 0.77 |
Gross Margin | 75.53% | 77.50% | 74.96% | 78.76% | 78.65% | 78.54% |
Operating Margin | -26.70% | -27.68% | -44.40% | -16.53% | -8.17% | 6.23% |
Profit Margin | -27.66% | -27.86% | -40.65% | -17.21% | -10.91% | 4.01% |
Free Cash Flow Margin | -10.15% | -11.44% | -19.72% | 1.75% | 10.95% | 17.03% |
EBITDA | -159.29 | -157.67 | -216.46 | -79.34 | -34.53 | 38.56 |
EBITDA Margin | -24.80% | -26.05% | -42.50% | -14.75% | -6.45% | 7.80% |
D&A For EBITDA | 12.17 | 9.87 | 9.7 | 9.57 | 9.17 | 7.75 |
EBIT | -171.45 | -167.54 | -226.16 | -88.91 | -43.69 | 30.81 |
EBIT Margin | -26.70% | -27.68% | -44.40% | -16.53% | -8.17% | 6.23% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.